Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,600.00
Bid: 1,598.00
Ask: 1,598.50
Change: -4.50 (-0.28%)
Spread: 0.50 (0.031%)
Open: 1,613.00
High: 1,613.00
Low: 1,589.00
Prev. Close: 1,604.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Citigroup And Goldman Downgrade Property Firms

Fri, 25th Jan 2019 09:47

LONDON (Alliance News) - The following London-listed shares received analyst recommendations Friday morning and late Thursday:----------FTSE 100----------GOLDMAN RAISES LAND SECURITIES TO 'NEUTRAL' ('SELL') - TARGET 769 (788) PENCE----------CITIGROUP CUTS LAND SECURITIES TO 'SELL' ('NEUTRAL') - TARGET 743 (974) PENCE----------GOLDMAN CUTS BRITISH LAND PRICE TARGET TO 589 (620) PENCE - 'NEUTRAL'----------CITIGROUP CUTS BRITISH LAND TO 'SELL' ('NEUTRAL') - TARGET 452 (647) PENCE----------GOLDMAN CUTS SEGRO PRICE TARGET TO 701 (716) PENCE - 'BUY'----------SOCGEN CUTS ITV TO 'HOLD' ('BUY') - TARGET 138 (190) PENCE----------SHORE CAPITAL RAISES ASTRAZENECA TO 'BUY' ('HOLD')----------HSBC SEES GLAXOSMITHKLINE AS ONE OF THE BEST GLOBAL STOCK IDEAS----------RBC CUTS BHP GROUP PRICE TARGET TO 1500 (1525) PENCE - 'SECTOR PERFORM'----------HSBC RAISES ANGLO AMERICAN PRICE TARGET TO 2120 (2100) PENCE - 'BUY'----------UBS RAISES FRESNILLO TO 'BUY' ('NEUTRAL') - TARGET 1100 (900) PENCE----------JPMORGAN CUTS KINGFISHER PRICE TARGET TO 200 (220) PENCE - 'UNDERWEIGHT'----------GOLDMAN RAISES AB FOODS PRICE TARGET TO 2600 (2500) PENCE - 'NEUTRAL'----------GOLDMAN RAISES SEVERN TRENT PRICE TARGET TO 1847 (1763) PENCE - 'SELL'----------BERNSTEIN CUTS VODAFONE PRICE TARGET TO 225 (235) PENCE - 'OUTPERFORM'----------JPMORGAN CUTS VODAFONE PRICE TARGET TO 230 (240) PENCE - 'OVERWEIGHT'----------DEUTSCHE BANK CUTS ST JAMES'S PLACE PRICE TARGET TO 1070 (1090) PENCE - 'HOLD'----------CREDIT SUISSE CUTS RBS PRICE TARGET TO 280 (295) PENCE - 'NEUTRAL'----------CREDIT SUISSE CUTS LLOYDS PRICE TARGET TO 84 (90) PENCE - 'OUTPERFORM'----------CREDIT SUISSE CUTS BARCLAYS PRICE TARGET TO 190 (210) PENCE - 'NEUTRAL'----------EXANE BNP RAISES HALMA TO 'OUTPERFORM' ('NEUTRAL') - TARGET 1550 (1350) PENCE----------EXANE BNP CUTS SPIRAX-SARCO TO 'UNDERPERFORM' (N) - TARGET 5700 (6300) PENCE----------FTSE 250----------GOLDMAN CUTS INTU PROPERTIES TO 'SELL' ('NEUTRAL') - TARGET 92 (117) PENCE----------CITIGROUP CUTS INTU PROPERTIES TO 'SELL' ('NEUTRAL') - TARGET 69 (190) PENCE----------CITIGROUP CUTS HAMMERSON TO 'SELL' ('NEUTRAL') - TARGET 278 (465) PENCE----------GOLDMAN CUTS HAMMERSON PRICE TARGET TO 367 (441) PENCE - 'NEUTRAL'----------CITIGROUP CUTS GREAT PORTLAND TO 'SELL' ('NEUTRAL') - TARGET 592 (691) PENCE----------GOLDMAN CUTS GREAT PORTLAND PRICE TARGET TO 633 (662) PENCE - 'NEUTRAL'----------GOLDMAN CUTS DERWENT LONDON PRICE TARGET TO 2960 (2976) PENCE - 'NEUTRAL'----------CITIGROUP CUTS DERWENT LONDON TO 'SELL' ('NEUTRAL') - TARGET 2513 (3186) PENCE----------GOLDMAN CUTS SHAFTESBURY PRICE TARGET TO 748 (806) PENCE - 'SELL'----------CITIGROUP CUTS SHAFTESBURY TO 'NEUTRAL' ('BUY') - TARGET 872 (1229) PENCE----------GOLDMAN CUTS BIG YELLOW GROUP PRICE TARGET TO 972 (993) PENCE - 'NEUTRAL'----------UBS CUTS CAPITAL & COUNTIES PRICE TARGET TO 310 (320) PENCE - 'BUY'----------JPMORGAN CUTS TRAVIS PERKINS PRICE TARGET TO 1330 (1400) PENCE - 'NEUTRAL'----------HSBC INITIATES CRANSWICK WITH 'HOLD' - TARGET 2810 PENCE----------HSBC INITIATES DAIRY CREST GROUP WITH 'BUY' - TARGET 570 PENCE----------HSBC INITIATES GREENCORE WITH 'BUY' - TARGET 270 PENCE----------HSBC INITIATES HILTON FOOD WITH 'HOLD' - TARGET 920 PENCE----------EXANE BNP RAISES PHOENIX GROUP TARGET TO 800 PENCE - 'OUTPERFORM'----------UBS CUTS SOPHOS PRICE TARGET TO 400 (440) PENCE - 'BUY'----------LIBERUM RESUMES RESTAURANT GROUP WITH 'HOLD' - TARGET 180 PENCE----------EXANE BNP CUTS SPECTRIS TO 'NEUTRAL' ('OUTPERFORM') - TARGET 2350 (2550) PENCE----------OTHER MAIN MARKET AND AIM----------CREDIT SUISSE CUTS DAILY MAIL PRICE TARGET TO 685 (770) PENCE - 'NEUTRAL'---------BARCLAYS CUTS DAILY MAIL PRICE TARGET TO 570 (605) PENCE - 'UNDERWEIGHT'----------GOLDMAN CUTS SECURE INCOME REIT PRICE TARGET TO 417 (446) PENCE - 'BUY'----------RBC CUTS FEVERTREE DRINKS PRICE TARGET TO 3400 (3600) PENCE - 'OUTPERFORM'----------DEUTSCHE BANK RAISES FEVERTREE DRINKS TARGET TO 2800 (2700) PENCE - 'HOLD'----------BERENBERG RAISES CONNECT GROUP PRICE TARGET TO 40 (35) PENCE - 'HOLD'----------LIBERUM RESUMES BURFORD CAPITAL WITH 'BUY' - TARGET 2300 PENCE----------

More News
23 Jun 2023 08:52

LONDON MARKET OPEN: Stocks down after BoE; GSK up on Zantac settlement

(Alliance News) - Stock prices in London opened lower on Friday, as rising interest rates weighed on housebuilding stocks in the FTSE 100.

Read more
23 Jun 2023 08:29

GSK reaches settlement in Goetz Zantac lawsuit

(Sharecast News) - GSK updated the market on the litigation regarding the now-discontinued heartburn drug ranitidine, or 'Zantac', on Friday.

Read more
23 Jun 2023 08:23

TOP NEWS: GSK reaches settlement in California Zantac lawsuit

(Alliance News) - GSK PLC on Friday said a Zantac trial set to begin next month in California has been dismissed after it reached a confidential settlement.

Read more
23 Jun 2023 08:19

Europe open: Stocks on the defensive after weak PMIs, euro awalloped

(Sharecast News) - Stocks on the Continent were trading on the back foot following the release of much weaker than expected readings for euro area factory and services activity.

Read more
23 Jun 2023 07:58

LONDON BRIEFING: GSK settles Zantac litigation in California

(Alliance News) - Stocks in London are set to open in the red on Friday, as risk sentiment across the globe is damped by hawkish central banks.

Read more
23 Jun 2023 07:42

European stocks head for worst week since March

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

EUROPEAN STOCKS HEAD FOR WORST WEEK SINCE MARCH (0638 GMT)

Read more
22 Jun 2023 09:26

GSK says Arexvy recommended in over 60s by US CDC committee

(Alliance News) - GSK PLC on Thursday said the US Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices has voted to recommend the firm's Arexvy jab in adults aged 60 and older.

Read more
22 Jun 2023 07:51

US CDC votes to recommend GSK's Arexvy against RSV

(Sharecast News) - America's public health watchdog endorsed GSK's Arexvy for use against Respiratory Syncytial Virus in adults over 60.

Read more
21 Jun 2023 23:10

US CDC advisers recommend older adults may receive Pfizer, GSK shots for RSV

June 21 (Reuters) - A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday recommended that new vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections be available to older adults in the U.S. but stopped short of saying all of them should get the shots.

Read more
21 Jun 2023 22:10

US CDC advisers back use of GSK, Pfizer RSV vaccines in older adults

June 21 (Reuters) - A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday recommended that adults aged 60 and above may receive the recently approved vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections. (Reporting by Raghav Mahobe in Bengaluru and Michael Erman in New York; Editing by Leslie Adler)

Read more
21 Jun 2023 11:00

US CDC advisers weigh use of GSK, Pfizer RSV vaccines in older adults

June 21 (Reuters) - A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday will vote on whether to recommend the use of recently approved vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections in older adults.

Read more
21 Jun 2023 09:19

GSK unveils positive trial results for vaccine against RSV

(Sharecast News) - GSK unveiled unveiled successful third phase clinical trial results for its Arexvy vaccine against respiratory syncytial virus in older adults.

Read more
21 Jun 2023 08:20

TOP NEWS: GSK reports positive data for RSV Arexvy vaccine

(Alliance News) - GSK PLC on Wednesday reported positive data for Arexvy, its respiratory syncytial virus vaccine for older adults.

Read more
20 Jun 2023 17:20

Miners, oil drag London stocks lower after modest China rate cut

Miners down as metal prices fall on strong dollar, China worries

*

Read more
20 Jun 2023 08:33

Lab crunch: British science has nowhere to go

OXFORD, England, June 20 (Reuters) - For Ros Deegan, the thrill of raising $100 million to expand a biotech firm among the dreaming spires of Oxford was soon tempered: unable to find a bigger laboratory, she routinely had to work at home.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.